Interview with Christian Schilling, CEO, Boehringer Ingelheim Austria
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
Address: ‘Dr.-Boehringer-Gasse 5-11
A-1121 Wien’
,Austria
Tel: (+43 1) 80 105-0
Web: http://www.boehringer-ingelheim.at/
Boehringer Ingelheim – one of the world‘s 20 leading pharmaceutical companies
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
For more information please visit www.boehringer-ingelheim.com
Boehringer Ingelheim in Austria
Boehringer Ingelheim founded its first subsidiary outside Germany in a Viennese pharmacy in 1948. From these modest beginnings, the Austrian company has developed into a modern high technology concern.
Today the company is of great importance as a cancer research centre and one of the three biopharmaceutical research, development and production centres in the international group. As the Regional Center Vienna it is responsible for the pharmaceutical business (human pharmaceuticals and animal health) and for clinical trials in more than 30 countries in Central and Eastern Europe (including Austria).
Over the last years Boehringer Ingelheim has created 530 new jobs in Vienna and invested around 360 million euros in the Vienna site.
Activities of the Boehringer Ingelheim Regional Center Vienna
• Business responsiblity for Boehringer Ingelheim products in more than 30 countries of Central and Eastern Europa – Human Pharmaceuticals and Animal Health
• International Oncology Research Center
• Clinical Research in all therapeutic areas of the Corporation in Central and Eastern Europe (including Austria and Switzerland), Turkey, South Africa and Israel
• Biopharmaceutical research, development and production
Boehringer Ingelheim Regional Center Vienna
The Regional Center Vienna (RCV) is responsible for the human pharmaceuticals (prescription medicines and over-the-counter products) and animal health business in more than 30 Central and Eastern European countries. Moreover the whole clinical research of the region is managed by the RCV. Vienna is the oncology research center and a center of biopharmaceutical research, development and production in the international group of companies. Boehringer Ingelheim is also engaged in basic research, represented by the Research Institute of Molecular Pathology (IMP) in Vienna. Therefore BI is one of the most research focused pharmaceutical companies in Austria. In 2011 the Boehringer Ingelheim Regional Center Vienna earned 736,2 million euros and had about 3,000 employees in Austria and Eastern Europe.
Animal Health
International Research Center of Oncology
Clinical research in all therapeutic areas of the business association – studies in 15 countries of Central and Eastern Europe (including Austria)
Biopharmaceutical development and manufacturing of pharmaceuticals
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
You have had an extensive career at the company, since 1989. What does the company have to offer that has made you stay so long and dedicated? AbbVie is a…
Previously you worked for a pharmaceutical company, before moving to head up Eucodis Bioscience. What was your main motivation for switching from the pharmaceutical to the industrial biotech industry? The…
Could you please provide an overview of your main scope of activities in Austria and the importance of healthcare and pharmaceuticals to Boston Consulting Group’s (BCG) business model and revenue?…
Prior to joining Kedrion you worked for CSL Behring for a number of years. What opportunities did you see for yourself in moving from there to Kedrion? The biggest opportunity…
LISAvienna celebrated its tenth anniversary in September. Could you briefly describe the core activities and organizational structure that has developed over the last decade? Austria has historically been quite strong…
Prior to founding Vela, you worked in a number of different positions with various companies such as Baxter and Octapharma. What opportunities did you see in founding your own company?…
You have been the CEO of Herba Chemosan since 2002. What were the initial goals you set for yourself when you took up this position, and where do we find…
Can you give our readers a brief overview of Daiichi Sankyo in Austria as well as its market positioning and growth factors in 2012? Daiichi Sankyo Austria GmbH is the…
How does the Austrian affiliate fit within Quintiles’ global structure, and what is the scope of the company’s activities here? Quintiles Austria was established in 1996 and has grown from…
Could you give our readers a snapshot of the association and its role in the Austrian pharmaceutical context? FOPI is a small and specialized industry association that has a homogenous…
Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today?…
2012 marks the twentieth anniversary of Polymun. Can you describe to our readers the origins of the company and how it compares to your expectations in 1992? Prior to founding…
See our Cookie Privacy Policy Here
